103 related articles for article (PubMed ID: 23803017)
1. Oncogenesis and the clinical significance of K-ras in pancreatic adenocarcinoma.
Huang C; Wang WM; Gong JP; Yang K
Asian Pac J Cancer Prev; 2013; 14(5):2699-701. PubMed ID: 23803017
[TBL] [Abstract][Full Text] [Related]
2. A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth.
Ehrhardt GR; Korherr C; Wieler JS; Knaus M; Schrader JW
Oncogene; 2001 Jan; 20(2):188-97. PubMed ID: 11313946
[TBL] [Abstract][Full Text] [Related]
3. Depletion of K-Ras promotes proteasome degradation of survivin.
Tecleab A; Sebti SM
Cell Cycle; 2013 Feb; 12(3):522-32. PubMed ID: 23324341
[TBL] [Abstract][Full Text] [Related]
4. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
5. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.
Nussinov R; Tsai CJ; Muratcioglu S; Jang H; Gursoy A; Keskin O
Expert Rev Proteomics; 2015; 12(6):669-82. PubMed ID: 26496174
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
9. Activation of Raf-1 in human pancreatic adenocarcinoma.
Berger DH; Jardines LA; Chang H; Ruggeri B
J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas.
Lu L; Zeng J
PLoS One; 2017; 12(7):e0181532. PubMed ID: 28742845
[TBL] [Abstract][Full Text] [Related]
11. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf.
Fuller SJ; Finn SG; Downward J; Sugden PH
Biochem J; 1998 Oct; 335 ( Pt 2)(Pt 2):241-6. PubMed ID: 9761720
[TBL] [Abstract][Full Text] [Related]
14. Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways.
Kaul A; Overmeyer JH; Maltese WA
Cell Signal; 2007 May; 19(5):1034-43. PubMed ID: 17210246
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase.
Kazama H; Yonehara S
J Cell Biol; 2000 Feb; 148(3):557-66. PubMed ID: 10662780
[TBL] [Abstract][Full Text] [Related]
16. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
17. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
18. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.
Hofer F; Fields S; Schneider C; Martin GS
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11089-93. PubMed ID: 7972015
[TBL] [Abstract][Full Text] [Related]
19. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
20. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
